Table of Contents
ISRN Ophthalmology
Volume 2014, Article ID 950975, 7 pages
Research Article

Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience

1Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
2Department of Radiation Oncology, Intermountain Medical Center, 5131 Cottonwood Street, Murray, UT 84107, USA
3Rocky Mountain Retina Associates, Murray, UT 84107, USA
4Retina Associates of Utah, Murray, UT 84107, USA

Received 31 December 2013; Accepted 11 February 2014; Published 9 March 2014

Academic Editors: M. N. Burnier Jr., M. Nakazawa, and H. Quiroz-Mercado

Copyright © 2014 Aaron Wagner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate our community-based institutional experience with plaque brachytherapy for uveal melanomas with a focus on local control rates, factors impacting disease progression, and dosimetric parameters impacting treatment toxicity. Methods and Materials. Our institution was retrospectively reviewed from 1996 to 2011; all patients who underwent plaque brachytherapy for uveal melanoma were included. Follow-up data were collected regarding local control, distant metastases, and side effects from treatment. Analysis was performed on factors impacting treatment outcomes and treatment toxicity. Results. A total of 107 patients underwent plaque brachytherapy, of which 88 had follow-up data available. Local control at 10 years was 94%. Freedom from progression (FFP) and overall survival at 10 years were 83% and 79%, respectively. On univariate analysis, there were no tumor or dosimetric treatment characteristics that were found to have a prognostic impact on FFP. Brachytherapy treatment was well tolerated, with clinically useful vision ( 20/200) maintained in 64% of patients. Statistically significant dosimetric relationships were established with cataract, glaucoma, and retinopathy development (greatest ). Conclusions. Treatment with plaque brachytherapy demonstrates excellent outcomes in a community-based setting. It is well tolerated and should remain a standard of care for COMS medium sized tumors.